Ruth Ann Marrie1. 1. Departments of Internal Medicine and Community Health Sciences, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, Canada. rmarrie@hsc.mb.ca.
Abstract
PURPOSE: Multiple sclerosis (MS) is an inflammatory and degenerative condition affecting the central nervous system. Like many neurologic diseases, it is chronic and incurable, and confers a substantial burden on affected individuals, their families and society. Although many individuals suffering from a serious chronic disease also suffer from comorbid conditions, the important consequences of their interaction often receive little attention. This was particularly true for MS two decades ago. Broadening our perspective by better understanding the effects of comorbidity on an individual with a particular chronic disease offers us an opportunity to improve understanding of prognosis, personalize disease management, develop new therapeutic approaches and illuminate the pathophysiology of disease. SOURCE: Studies examining the incidence, prevalence and outcomes related to comorbidity in MS will be discussed, along with areas requiring further investigation. CONCLUSION: Comorbidity is highly prevalent in MS throughout the disease course. Comorbid conditions, including depression, anxiety, hypertension, hyperlipidemia, diabetes and chronic lung disease, adversely affect a broad range of outcomes. Less is known about the effects of MS on outcomes related to these comorbid conditions. These findings highlight an urgent need to determine how to best prevent and treat comorbidity in MS.
PURPOSE:Multiple sclerosis (MS) is an inflammatory and degenerative condition affecting the central nervous system. Like many neurologic diseases, it is chronic and incurable, and confers a substantial burden on affected individuals, their families and society. Although many individuals suffering from a serious chronic disease also suffer from comorbid conditions, the important consequences of their interaction often receive little attention. This was particularly true for MS two decades ago. Broadening our perspective by better understanding the effects of comorbidity on an individual with a particular chronic disease offers us an opportunity to improve understanding of prognosis, personalize disease management, develop new therapeutic approaches and illuminate the pathophysiology of disease. SOURCE: Studies examining the incidence, prevalence and outcomes related to comorbidity in MS will be discussed, along with areas requiring further investigation. CONCLUSION: Comorbidity is highly prevalent in MS throughout the disease course. Comorbid conditions, including depression, anxiety, hypertension, hyperlipidemia, diabetes and chronic lung disease, adversely affect a broad range of outcomes. Less is known about the effects of MS on outcomes related to these comorbid conditions. These findings highlight an urgent need to determine how to best prevent and treat comorbidity in MS.
Authors: Antonio Reia; Martina Petruzzo; Fabrizia Falco; Teresa Costabile; Matteo Conenna; Antonio Carotenuto; Maria Petracca; Giuseppe Servillo; Roberta Lanzillo; Vincenzo Brescia Morra; Marcello Moccia Journal: Brain Sci Date: 2021-04-16
Authors: Bruce F Bebo; Mark Allegretta; Douglas Landsman; Kathy M Zackowski; Fiona Brabazon; Walter A Kostich; Timothy Coetzee; Alexander Victor Ng; Ruth Ann Marrie; Kelly R Monk; Amit Bar-Or; Caroline C Whitacre Journal: Mult Scler Date: 2022-03 Impact factor: 6.312
Authors: Jagadeswara Rao Earla; George J Hutton; J Douglas Thornton; Hua Chen; Michael L Johnson; Rajender R Aparasu Journal: Explor Res Clin Soc Pharm Date: 2021-05-05
Authors: Jane Louisa Debus; Paula Bachmann; Niklas Frahm; Pegah Mashhadiakbar; Silvan Elias Langhorst; Barbara Streckenbach; Julia Baldt; Felicita Heidler; Michael Hecker; Uwe Klaus Zettl Journal: Ther Adv Chronic Dis Date: 2022-08-04 Impact factor: 4.970
Authors: Jan Spaas; Richie P Goulding; Charly Keytsman; Lena Fonteyn; Jack van Horssen; Richard T Jaspers; Bert O Eijnde; Rob C I Wüst Journal: J Cachexia Sarcopenia Muscle Date: 2022-08-04 Impact factor: 12.063
Authors: Jagadeswara R Earla; George J Hutton; J Douglas Thornton; Hua Chen; Michael L Johnson; Rajender R Aparasu Journal: Patient Prefer Adherence Date: 2020-11-04 Impact factor: 2.711